Now showing items 1-3 of 3

    • Acquired genetic events and NF1 mutations in advanced breast cancer 

      Pearson, A; Proszek, P; Pascual, J; Fribbens, C; Shamsher, M; Kingston, B; O'Leary, B; Herrera-Abreu, M; Cutts, R; Garcia-Murillas, I; Bye, H; Walker, B; Gonzalez, D; Yuan, L; Jamal, S; Hubank, M; Lopez-Knowles, E; Schuster, E; Dowsett, M; Osin, P; Nerurkar, A; Parton, M; Okines, A; Johnston, S; Ring, A; Turner, N
    • Inactivating NF1 Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy Resistance. 

      Pearson, A; Proszek, P; Pascual, J; Fribbens, C; Shamsher, MK; Kingston, B; O'Leary, B; Herrera-Abreu, MT; Cutts, RJ; Garcia-Murillas, I; Bye, H; Walker, BA; Gonzalez De Castro, D; Yuan, L; Jamal, S; Hubank, M; Lopez-Knowles, E; Schuster, EF; Dowsett, M; Osin, P; Nerurkar, A; Parton, M; Okines, AFC; Johnston, SRD; Ring, A; Turner, NC (2020-02)
      PURPOSE:Advanced breast cancer (ABC) has not been subjected to the same degree of molecular scrutiny as early primary cancer. Breast cancer evolves with time and under the selective pressure of treatment, with the potential ...
    • Targeting the PI3-kinase pathway in triple-negative breast cancer. 

      Pascual, J; Turner, NC (2019-07)
      Triple-negative breast cancer (TNBC) is characterised by poor outcomes and a historical lack of targeted therapies. Dysregulation of signalling through the phosphoinositide 3 (PI3)-kinase and AKT signalling pathway is one ...